上海糖霁生物科技

Tangji Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative therapies for metabolic and chronic diseases. The company utilizes a proprietary glyco-engineering platform to optimize the pharmacological properties of protein drugs, with a specific focus on fibroblast growth factors (FGFs). Its lead candidate, TJ011, is a long-acting FGF21 analog currently in Phase 2 clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). Tangji Bio also explores the potential of its FGF pipeline in treating obesity and type 2 diabetes. Backed by top-tier investors like GL Ventures and Lilly Asia Ventures, the company aims to address significant unmet needs in global metabolic health. Its scientific foundation is built upon decades of research in glycobiology and protein engineering.